Laboratorios [ROVI] vs Grifols, S.A [GRF] Detailed Stock Comparison

Laboratorios Farmaceuticos Rovi S.A.

BME
Loading...

Grifols, S.A.

BME
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Laboratorios Farmaceuticos Rovi S.A. wins in 12 metrics, Grifols, S.A. wins in 8 metrics, with 0 ties. Laboratorios Farmaceuticos Rovi S.A. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Laboratorios Farmaceuticos Rovi S.A. Grifols, S.A. Better
P/E Ratio (TTM) 36.12 15.58 Grifols, S.A.
Price-to-Book Ratio 6.59 1.19 Grifols, S.A.
Debt-to-Equity Ratio 18.04 126.83 Laboratorios Farmaceuticos Rovi S.A.
PEG Ratio 19.85 7.76 Grifols, S.A.
EV/EBITDA 22.52 10.24 Grifols, S.A.
Profit Margin (TTM) 18.89% 5.34% Laboratorios Farmaceuticos Rovi S.A.
Operating Margin (TTM) 25.15% 17.53% Laboratorios Farmaceuticos Rovi S.A.
EBITDA Margin (TTM) 25.15% 17.53% Laboratorios Farmaceuticos Rovi S.A.
Return on Equity 22.33% 6.17% Laboratorios Farmaceuticos Rovi S.A.
Return on Assets (TTM) 12.11% 4.24% Laboratorios Farmaceuticos Rovi S.A.
Free Cash Flow (TTM) $76.06M $624.00M Grifols, S.A.
Dividend Yield 1.69% 1.39% Laboratorios Farmaceuticos Rovi S.A.
1-Year Return 58.55% 5.17% Laboratorios Farmaceuticos Rovi S.A.
Price-to-Sales Ratio (TTM) 5.89 0.83 Grifols, S.A.
Enterprise Value $4.40B $17.38B Grifols, S.A.
EV/Revenue Ratio 5.92 2.31 Grifols, S.A.
Gross Profit Margin (TTM) 70.23% 34.66% Laboratorios Farmaceuticos Rovi S.A.
Revenue per Share (TTM) $15 $11 Laboratorios Farmaceuticos Rovi S.A.
Earnings per Share (Diluted) $2.37 $0.59 Laboratorios Farmaceuticos Rovi S.A.
Beta (Stock Volatility) 0.33 1.21 Laboratorios Farmaceuticos Rovi S.A.

Laboratorios Farmaceuticos Rovi S.A. vs Grifols, S.A. Stock Performance Analysis

Loading Price Chart...

ROVI
GRF

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Laboratorios Farmaceuticos Rovi S.A.-4.48%-4.70%3.25%11.63%25.93%28.02%
Grifols, S.A.0.00%-7.25%1.24%-18.49%-20.87%-20.02%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Laboratorios Farmaceuticos Rovi S.A.58.55%101.84%68.26%449.09%1,459.62%743.04%
Grifols, S.A.5.17%-3.97%-60.31%-52.89%33.98%244.23%

Performance & Financial Health Analysis: Laboratorios Farmaceuticos Rovi S.A. vs Grifols, S.A.

MetricROVIGRF
Market Information
Market Cap i€4.34B€6.09B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i83,5943,094,066
90 Day Avg. Volume i105,9902,725,724
Last Close€81.10€8.95
52 Week Range€50.05 - €86.70€8.01 - €13.70
% from 52W High-6.46%-34.67%
All-Time High€94.80 (May 27, 2024)€34.31 (Feb 17, 2020)
% from All-Time High-14.45%-73.91%
Growth Metrics
Quarterly Revenue Growth0.10%0.00%
Quarterly Earnings Growth0.83%0.42%
Financial Health
Profit Margin (TTM) i0.19%0.05%
Operating Margin (TTM) i0.25%0.18%
Return on Equity (TTM) i0.22%0.06%
Debt to Equity (MRQ) i18.04126.83
Cash & Liquidity
Book Value per Share (MRQ)€12.99€7.75
Cash per Share (MRQ)€1.93€1.25
Operating Cash Flow (TTM) i€187.08M€1.05B
Levered Free Cash Flow (TTM) i€82.30M€1.03B
Dividends
Last 12-Month Dividend Yield i1.69%1.39%
Last 12-Month Dividend i€0.94€0.15

Valuation & Enterprise Metrics Analysis: Laboratorios Farmaceuticos Rovi S.A. vs Grifols, S.A.

MetricROVI (Apr 24, 2026)GRF (Apr 23, 2026)
Price Ratios
P/E Ratio (TTM) i36.1215.58
Forward P/E i19.857.76
PEG Ratio i19.857.76
Price to Sales (TTM) i5.890.83
Price to Book (MRQ) i6.591.19
Market Capitalization
Market Capitalization i€4.34B€6.09B
Enterprise Value i€4.40B€17.38B
Enterprise Value Metrics
Enterprise to Revenue i5.922.31
Enterprise to EBITDA i22.5210.24
Risk & Other Metrics
Beta i0.331.21
Book Value per Share (MRQ) i€12.99€7.75

Financial Statements Comparison: Laboratorios Farmaceuticos Rovi S.A. vs Grifols, S.A.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricROVI (2024)GRF (2025)
Revenue/Sales i763.75M7.52B
Cost of Goods Sold i285.40M4.67B
COGS % of Revenue i37.4%62.0%
Gross Profit i478.35M2.86B
Gross Margin i62.6%38.0%
Research & Development iN/A426.00M
Operating Income (EBIT) i179.55M1.25B
Operating Margin i23.5%16.6%
EBITDA i207.61M1.66B
EBITDA Margin i27.2%22.1%
Pre-Tax Income i177.69M615.00M
Pre-Tax Income % of Revenue i23.3%8.2%
Income Tax i40.81M115.00M
Income Tax % of Revenue i5.3%1.5%
Net Income (Profit) i136.88M500.00M
Profit Margin i17.9%6.6%

Balance Sheet & Liquidity Metrics

MetricROVI (2024)GRF (2025)
Cash & Equivalents i27.19M801.00M
Total Current Assets i489.61M5.07B
Total Current Assets % of Revenue i64.1%67.4%
Total Current Liabilities i156.65M2.02B
Total Current Liabilities % of Revenue i20.5%26.8%
Long-Term Debt i90.72M9.04B
Long-Term Debt % of Revenue i11.9%120.2%
Total Shareholders Equity i581.54M7.60B
Retained Earnings i486.21M300.00M
Retained Earnings % of Revenue i63.7%4.0%
Property, Plant & Equipment i116.64M0

Cash Flow Statement Comparison

MetricROVI (2024)GRF (2025)
Operating Cash Flow i203.90M1.59B
Operating Cash Flow % of Revenue i26.7%21.1%
Capital Expenditures i-59.08M-261.00M
Free Cash Flow i76.06M624.00M
FCF Margin i10.0%8.3%
Debt Repayment i-51.71M-119.00M
Common Stock Repurchase i-89.71MN/A

Short Interest & Institutional Ownership Analysis

MetricROVIGRF
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i51.15M680.58M
Float Shares i16.30M417.32M
% Held by Insiders i68.03%31.68%
% Held by Institutions i19.15%33.52%
% Held by Public i12.82%34.80%

Dividend Analysis & Yield Comparison: Laboratorios Farmaceuticos Rovi S.A. vs Grifols, S.A.

MetricROVIGRF
Last 12-Month Dividend i€0.94€0.15
Last 12-Month Dividend Yield i1.69%1.39%
3-Year Avg Annual Dividend i€1.11€0.05
3-Year Avg Dividend Yield i2.08%1.20%
3-Year Total Dividends i€3.33€0.15
Ex-Dividend DateJul 14, 2025Aug 11, 2025